# Auto Review: results.txt

Generated: 2026-04-29 10:33
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 30
- **Clean**: 0/30
- **P0** (hallucination): 0
- **P1** (major error): 8
- **P2** (minor issue): 138

### Critical Issues

- **ROW 7** [P1]: Inaccurate staging information. The correct stage is pT3 N1, not Stage II-III.
- **ROW 14** [P1]: The sentence does not specify that the tumor is of duodenal origin, which is important information.
- **ROW 15** [P1]: The plan is to resume an unspecified agent, not specifically oxaliplatin.
- **ROW 21** [P1]: Incomplete sentence, missing critical information about the specific dose reduction.
- **ROW 36** [P1]: Incomplete sentence with missing critical information (dose number).
- **ROW 40** [P1]: Incomplete sentence with missing critical information (lacks the specific dose increase).
- **ROW 43** [P1]: Incomplete sentence with missing critical information. The sentence mentions 'slowly declining' but does not clarify the trend clearly.
- **ROW 90** [P1]: Incomplete sentence with missing critical information.

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: Potentially resectable with a regional LN involvement

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (palonosetron). | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Lab_Results | Missing CA 19-9 value from initial diagnosis. | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |
| P2 | Treatment_Changes | Missing mention of palonosetron as a supportive med. | Start 2 days after last dose of palonosetron (*****) is given. |
| P2 | Treatment_Goals | Inaccurate goal classification. Should be 'neoadjuvant'. | We reviewed his most recent imaging studies which show, quite encouragingly, resolution of his aorto |
| P2 | Radiotherapy_plan | Uncertainty about radiotherapy role should be mentioned. | While the optimal selection and duration of systemic therapy, as well as the uncertain role of radia |

*Extraction summary*: Most fields are accurate, but there are minor issues with missing cancer-related medications, incomplete lab results, and slight misclassification of treatment goals.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Metastatic pancreatic ductal adenocarcinoma
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine-based regimen mentioned as a potential future treatment, but not listed under current medications). | We talked about potential side fx and risks, esp in terms of infectious complications, and adverse i |
| P2 | Treatment_Changes | Supportive medications listed include general pain medications (Fentanyl patch, Dilaudid) without specifying they are for cancer pain. | Symptom-wise, he is followed by our Cancer Center Symptom Management Service; his pain appears reaso |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medication and imprecise classification of supportive medications.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained jargon 'peritoneal carcinomatosis'. | Additionally, the peritoneal carcinomatosis has slightly worse large volume asci |
| P2 | Unexplained jargon 'pancolitis'. | There is no evidence of bowel obstruction, and pancolitis has nearly resolved wi |

*Letter summary*: Letter contains minor readability issues due to unexplained medical jargon.

---

## ROW 6 — ⚠️ ISSUES

**Type**: Pancreatic neuroendocrine tumor, grade 2
**Stage**: now metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Type_of_Cancer | The note mentions both grade 1 and grade 2, but the extracted data only states grade 2. | Pathology(+) 5.5cm well-differentiated neuroendocrine tumor, grade 1 (ki-67% <2%)... Retroperitoneal |
| P2 | Clinical_Findings.findings | The extracted data does not mention the patient's ECOG PS 0, which is mentioned in the note. | Physical exam shows no palpable masses, jaundice, ascites, or significant weight loss. Patient is EC |

*Extraction summary*: Most fields are clean, but there are minor issues with the cancer grade and ECOG PS status.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'lymph nodes' is used without explanation, which may be jargon for an 8th-grade reading level. | Imaging findings show that the cancer in your liver and lymph nodes has grown si |
| P2 | The term 'MRI' is used without explanation, which may be jargon for an 8th-grade reading level. | MRI scans will be used to monitor the tumor's progress. |

*Letter summary*: Letter is mostly clean but contains minor readability issues with unexplained medical terms.

---

## ROW 7 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic ductal adenocarcinoma
**Stage**: pT3 N1

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. The note mentions metformin, methylphenidate, ondansetron, and oxycodone, but only ondansetron and oxycodone are listed under supportive_meds. | Medications the patient states to be taking prior to today's encounter. METFORMIN HCL (METFORMIN ORA |
| P2 | Treatment_Changes | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy, but the current_meds field only lists gemcitabine. | Beginning cycle #4 the [REDACTED]-paclitaxel was discontinued due to cumulative peripheral sensory n |
| P2 | Treatment_Goals | Inaccurate. The note suggests the goal is adjuvant therapy, not curative. The patient is receiving adjuvant chemotherapy after surgery. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and classification of treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate staging information. The correct stage is pT3 N1, not Stage II-III. | You have a well-differentiated pancreatic ductal adenocarcinoma (cancer that sta |
| P2 | Unexplained jargon 'labs'. | Your labs are noted to be significantly improved, allowing continuation of gemci |
| P2 | Unexplained jargon 'adjuvant chemotherapy', 'cumulative peripheral sensory neuropathy'. | You are currently receiving adjuvant chemotherapy with gemcitabine alone, having |

*Letter summary*: The letter contains inaccuracies and minor readability issues.

---

## ROW 14 — ⚠️ ISSUES

**Type**: High-grade neuroendocrine tumor of duodenal/ampullary origin
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Only 'capecitabine' is listed, but 'temozolomide' is also a cancer-related medication. | She is now s/p 5 cycles of chemotherapy consisting of the combination of capecitabine/temozolomide. |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence does not specify that the tumor is of duodenal origin, which is important information. | You came in for a follow-up visit regarding your neuroendocrine tumor treatment. |
| P2 | The term 'fluid buildup' might be confusing; 'ascites' is more precise. | During the physical exam, no masses, fluid buildup, or enlarged liver were found |
| P2 | This sentence is incomplete as it doesn't mention the dosing or frequency, though these details are intentionally omitted. | You will continue to take ondansetron and oxycodone to manage side effects. |
| P2 | The sentence lacks the detail about arranging for post-CT IV hydration. | After this cycle, you will have a CT scan with IV contrast to assess your tumor. |

*Letter summary*: The letter contains some inaccuracies and omissions that need addressing.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage is listed as 'Metastatic ()', which is incomplete and could be more precise. | This is a very pleasant 35-year-old Hispanic male who was diagnosed in October 2015 with metastatic  |
| P2 | Treatment_Changes.recent_changes | The note mentions concern about oxaliplatin due to residual neuropathy, but the plan is to resume an unspecified agent, not necessarily oxaliplatin. | He responded initially quite well to ***** but because of his residual neuropathy, I am concerned ab |
| P1 | Therapy_plan.therapy_plan | The plan is to resume an unspecified agent, not specifically oxaliplatin. | We will resume [REDACTED]. He responded initially quite well to [REDACTED] but because of his residu |

*Extraction summary*: Most fields are clean, but there are minor issues with the stage description and major issues with the therapy plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained jargon (oxaliplatin). | We will resume a medication. You responded initially quite well to a medication  |
| P2 | Unexplained jargon (omental, peritoneal metastases, ascites). | The cancer is showing progression with extensive peritoneal disease as evidenced |

*Letter summary*: Letter has minor readability issues due to unexplained medical jargon.

---

## ROW 17 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and capecitabine). | She has now had 4 full cycles and returns today for follow-up imaging. When we last saw her, she had |
| P2 | Treatment_Changes | Missing ongoing chemotherapy (gemcitabine and capecitabine). | She will continue on chemotherapy without dose or schedule modification and we will also start denos |
| P2 | Imaging_Plan | Inaccurate imaging plan, should include both CT Chest and CT Abdomen/Pelvis. | She will continue on chemotherapy without dose or schedule modification and we will also start denos |

*Extraction summary*: Most fields are clean, but there are minor issues regarding missing ongoing chemotherapy and an incomplete imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 18 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma, grade 2; Intra-ampullary papillary-tubular neo
**Stage**: Originally Stage IB, now metastatic (pt2n0)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | Medication Instructions section lists general medications only. |
| P2 | Treatment_Changes | Supportive medications listed are not fully supported by the note. | Supportive medications mentioned are ondansetron, prochlorperazine, and loperamide, but the note doe |
| P2 | Treatment_Goals | Goals of treatment are stated as 'palliative', but the note suggests a mix of palliative and surveillance strategies. | The note discusses ongoing monitoring and potential future treatments, suggesting a mixed approach. |
| P2 | Response_Assessment | The response assessment mentions a recent bump in CA 19-9 levels, but the exact level is not provided. | CA 19-9 levels are mentioned as having increased, but the specific value is not given. |
| P2 | Medication_Plan | The plan mentions unspecified agent and unspecified regimens, which are [REDACTED] in the note. | Specific drug names are [REDACTED] in the note, leading to incomplete medication plan. |
| P2 | Therapy_plan | The therapy plan mentions unspecified agent and unspecified regimens, which are [REDACTED] in the note. | Specific drug names are [REDACTED] in the note, leading to incomplete therapy plan. |
| P2 | Procedure_Plan | The procedure plan mentions unspecified procedure, which is [REDACTED] in the note. | Specific procedure name is [REDACTED] in the note, leading to incomplete procedure plan. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, incomplete supportive medications, and unspecified treatment details.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 21 — ⚠️ ISSUES

**Type**: Metastatic pancreatic cancer
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (5-FU/LV + irinotecan). | On this basis, he initiated 2nd-line chemotherapy consisting of the combination of 5-*****/LV plus * |
| P2 | Treatment_Changes | Missing detail about dose reduction of 5-FU/LV + irinotecan. | Due to obstipation and anorexia following cycle #1, his doses were reduced by 20% beginning with cyc |
| P2 | Treatment_Goals | Incomplete. Should include 'symptom management' along with 'palliative'. | Therefore we had a ***** goals of care discussion in which I recommended that he refocus his goals p |
| P2 | Medication_Plan | Incorrect. The patient is no longer a candidate for further chemotherapy. | At this point, he is no longer a candidate for any further salvage treatment in terms of either SOC  |
| P2 | Therapy_plan | Incorrect. The patient is no longer a candidate for further chemotherapy. | At this point, he is no longer a candidate for any further salvage treatment in terms of either SOC  |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medications, incomplete treatment goals, and incorrect therapy plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing critical information about the specific dose reduction. | Your chemotherapy doses were reduced by 20% starting with cycle #2 due to side e |

*Letter summary*: Letter contains an incomplete sentence regarding dose reduction.

---

## ROW 29 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | The summary mentions 'new diagnosis', which contradicts the note stating 'new diagnosis of metastatic adenocarcinoma of the pancreas'. | This is a very pleasant 61-year-old woman with a new diagnosis of metastatic adenocarcinoma of the p |
| P2 | Current_Medications.current_meds | The field only includes 'Gemcitabine, Abraxane', but the note mentions 'Lovenox' as part of the treatment. | She was started back on Lovenox. |
| P2 | Treatment_Changes.recent_changes | The field only includes 'Restarted Gemcitabine + Abraxane', but the note mentions 'Lovenox' as part of the recent changes. | She was started back on Lovenox. |
| P2 | Medication_Plan.medication_plan | The field only includes 'Gemcitabine, Abraxane, Lasix, spironolactone, Ritalin, Mirtazapine', but the note mentions 'Lovenox' as part of the medication plan. | She was started back on Lovenox. |
| P2 | Therapy_plan.therapy_plan | The field only includes 'Gemcitabine, Abraxane, lasix, home health', but the note mentions 'Lovenox' as part of the therapy plan. | She was started back on Lovenox. |

*Extraction summary*: Most fields are clean, but there are minor issues related to the inclusion of 'Lovenox' in the medication and treatment plans.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 31 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | Stage of cancer is missing, though it could be inferred as Stage IV due to metastasis. | Metastatic adenocarcinoma the pancreas improving on therapy with resolution of ascites |
| P2 | Current_Medications.current_meds | Missing specific details about the dosing and schedule of gemcitabine. | He is now been through 3 cycles of alternate week fixed dose rate gemcitabine. |
| P2 | Treatment_Changes.recent_changes | Field is empty, but there might be relevant changes in supportive care or other treatments not captured. | He continues on treatment without schedule or dose modification. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing stage information, incomplete medication details, and lack of recent treatment changes.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 32 — ⚠️ ISSUES

**Type**: Metastatic moderately differentiated adenocarcinoma of pancreatic or biliary ori
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine, atorvastatin, etc.) | Medications the patient states to be taking prior to today's encounter. |
| P2 | Treatment_Changes | Supportive medications listed are not exclusively cancer-related | Supportive medications include primary prophylaxis with growth factor support ([REDACTED] or Neupoge |
| P2 | Treatment_Goals | Goals of treatment should be more specific (e.g., palliative with disease control) | The goals of such treatment are to produce disease control and hopefully extend survival, while poss |
| P2 | Medication_Plan | Incomplete listing of chemotherapy agents (missing leucovorin) | The patient is inclined to move ahead with standard of care (SOC) chemotherapy with [REDACTED]. |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and specificity in medication and treatment plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained medical jargon 'metastases'. | You have a 6 cm irregular mass in the body of your pancreas with multiple liver  |
| P2 | Unexplained medical jargon 'growth factor support'. | Supportive medications include primary prophylaxis with growth factor support af |
| P2 | Unexplained medical jargon 'Mediport'. | You are scheduled to have a Mediport placed through your local oncologist. |

*Letter summary*: Letter contains minor readability issues related to unexplained medical jargon.

---

## ROW 33 — ⚠️ ISSUES

**Type**: Metastatic pancreatic adenocarcinoma with biopsy-proven liver metastasis
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (irinotecan). | She was started on ***** 06/07/19 and has been tolerating it well with dose reduction of irinotecan  |
| P2 | Treatment_Changes | Inaccurate description of recent treatment changes. Irinotecan was reduced, not switched. | She was started on ***** 06/07/19 and has been tolerating it well with dose reduction of irinotecan  |
| P2 | Treatment_Goals | Goals of treatment should be 'palliative' rather than 'palliative'. | my recommendation is to switch her therapy to gemcitabine combined with *****-paclitaxel. |
| P2 | Medication_Plan | Inconsistent mention of irinotecan. It should be removed since it's being switched. | Plan for gemcitabine 1000 mg/m2 + [REDACTED]-paclitaxel 125 mg/m2 on days 1, 8, 15 out of 28-day cyc |
| P2 | Therapy_plan | Inconsistent mention of irinotecan. It should be removed since it's being switched. | Continue irinotecan. Plan for gemcitabine 1000 mg/m2 + [REDACTED]-paclitaxel 125 mg/m2 on days 1, 8, |
| P2 | Lab_Plan | Incomplete lab plan. Should include monitoring of Carcinoembryonic Antigen and Cancer Antigen 19-9 levels. | We will monitor [REDACTED] levels monthly. |

*Extraction summary*: Most fields are clean, but there are minor issues with medication plans, treatment goals, and lab monitoring.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'enhancement' may be confusing to a layperson. | Recent imaging shows stable disease in the liver but progressive disease in the  |
| P2 | While 'Cancer Antigen 19-9' and 'Carcinoembryonic Antigen' are acceptable terms, they might still be confusing. | Your Cancer Antigen 19-9 and Carcinoembryonic Antigen levels remain high. |
| P2 | The term 'gemcitabine and nab-paclitaxel' might be confusing. | You will receive gemcitabine and nab-paclitaxel on days 1, 8, and 15 of a 28-day |

*Letter summary*: Letter contains minor readability issues that could be improved for clarity.

---

## ROW 35 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreatic tail with metastatic disease to liver
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions several medications that are not cancer-related. | Current Outpatient Prescriptions: ERGOCALCIFEROL, VITAMIN D2, escitalopram oxalate, lisinopril, lora |
| P2 | Treatment_Changes | The field is empty, but the note discusses potential future treatment changes based on lab results and clinical trials. | My recommendation would be consideration of the ***** trial to determine if the patient has high ser |

*Extraction summary*: Most fields are clean, but 'Current_Medications' and 'Treatment_Changes' are incomplete.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained jargon (EUS). | MRI and EUS tests showed a large pancreatic tumor and four liver tumors, suggest |
| P2 | Unexplained jargon (genetic counselor). | You will be referred to a genetic counselor to check for inherited cancer syndro |

*Letter summary*: Letter is mostly clean but contains minor readability issues related to unexplained medical jargon.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. The note mentions everolimus but does not include other cancer-related medications like Sandostatin (mentioned as poorly tolerated previously). | Previous treatment has included a distal pancreatectomy of her primary lesion back in 2002; several  |
| P2 | Treatment_Changes | Incomplete. The note mentions that everolimus was held during partial SBO but does not mention the specific dates or reasons for holding it. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Slightly imprecise. The note suggests 'good durable disease control' rather than just 'palliative'. | with evidence of good durable disease control and reasonably good (in fact, improved) tolerance on c |

*Extraction summary*: Most fields are clean, but there are minor issues related to completeness and precision in medication and treatment details.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (dose number). | Your dose of everolimus was reduced from 10 . This change was made in April 2012 |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine and Abraxane) in the current medications section. | We recommend a course of treatment with gemcitabine and Abraxane. |

*Extraction summary*: One minor issue identified in the Current_Medications field.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (lacks the specific dose increase). | We plan to increase the dose of your pain patch, and added Reglan and when neces |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 41 — ⚠️ ISSUES

**Type**: Invasive adenocarcinoma of pancreatic head, post-treatment tumor appears well- t
**Stage**: Not available (redacted), now with local recurrence

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (chemotherapy). | He initiated chemotherapy with ***** at full doses (minus the 5-***** bolus) beginning 05/15/2018, * |
| P2 | Treatment_Changes | Missing recent treatment changes. | ***** cycle (#12) was administered with 20% dose reductions in both oxaliplatin and irinotecan due t |
| P2 | Imaging_Plan | Missing recommendation for PET/CT. | Further evaluation with PET/CT may be helpful for confirmation. |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medications, treatment changes, and imaging recommendations.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Unexplained medical jargon 'CT scans' and 'liver lesion'. | Your recent CT scans show a decrease in size of a liver lesion, initially measur |
| P2 | Unexplained medical jargon 'soft tissue' and 'local recurrence'. | However, there is an increase in soft tissue near the surgical site, suggesting  |

*Letter summary*: Letter is mostly clean but contains minor readability issues related to unexplained medical jargon.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | The note mentions 'CA 19-9 = 115', 'CA 19-9 = 141', 'CA 19-9 = 80', 'CA 19-9 = 105', and 'CA 19-9 =  |

*Extraction summary*: One minor issue found in Current_Medications, otherwise all fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. The sentence mentions 'slowly declining' but does not clarify the trend clearly. | Your CA 19-9 levels, a tumor marker, have fluctuated during treatment but are sl |

*Letter summary*: The letter contains a minor issue with an incomplete sentence that requires clarification.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Well to moderately differentiated adenocarcinoma of the pancreas; Mucinous adeno
**Stage**: Likely advanced stage (likely or higher) due to positive retroperitoneal margin 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions several cancer-related medications such as propylthiouracil (PTU) for hyperthyroidism. | propylthiouracil (PTU) 50 mg tablet Take 25 mg by mouth. |
| P2 | Treatment_Changes | The field is empty, but the note mentions changes in medication dosages, such as lisinopril and omeprazole. | lisinopril (PRINIVIL,ZESTRIL) 40 mg tablet Take 20 mg (one half tablet) by mouth daily. (Patient tak |
| P2 | Imaging_Plan | The field only mentions 'CT Chest', but the note suggests ongoing surveillance which may include other imaging modalities. | She will continue on surveillance. We'll see her again in 6 months. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, treatment changes, and incomplete imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The sentence is vague and does not specify the type of cancer. | You came in for a follow-up visit regarding your cancer treatment. |
| P2 | The term 'groundglass nodule' may be confusing to a layperson. | A 6mm groundglass nodule in the left upper lobe of your lung remains unchanged s |

*Letter summary*: Letter is mostly clean but requires minor clarifications for accuracy and readability.

---

## ROW 62 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma
**Stage**: Originally pT3 N1, now metastatic (pt3 n1)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions 'Continuing abraxane.' | We will cont ***** ***** abraxane. |
| P2 | Treatment_Changes | The field only mentions starting treatment, but the note also states continuing abraxane. | We will cont ***** ***** abraxane. |
| P2 | Lab_Plan | The field states 'No labs planned,' but the note does not explicitly state no future labs are planned. | Labs including the CBC and chemistry profile were reviewed per protocol. |

*Extraction summary*: Most fields are clean, but there are minor issues with medication and lab plans.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 72 — ⚠️ ISSUES

**Type**: Moderately differentiated adenocarcinoma of the pancreas
**Stage**: Originally borderline resectable, now metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage description 'Originally borderline resectable, now metastatic ()' is slightly imprecise. It should specify the current stage as 'metastatic' without the original stage. | He had an episode of bursitis in his L elbow which is now resolved.     He  completed 4 cycles of th |
| P2 | Treatment_Changes.recent_changes | The recent changes mention switching to reduced dose [REDACTED], but the exact name of the medication is redacted. This could be clearer. | We then elected to resume chemotherapy but switched to reduced dose [REDACTED]. He did not tolerate  |

*Extraction summary*: Most fields are clean, but there are minor issues with the stage description and clarity of recent treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | Contains medical jargon that may be difficult for an 8th-grade reader to understand. | Your cancer is currently showing stable disease in the abdomen but progressing p |
| P2 | Mentions 'chemotherapy holiday' which may be confusing. | We decided to resume chemotherapy but switched to a reduced dose of a medication |

*Letter summary*: Letter contains minor readability issues with some medical jargon that could be simplified further.

---

## ROW 77 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the tail of the pancreas
**Stage**: Resectable at diagnosis, now with negative margins and lymph nodes

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary of the visit. It mentions 'follow-up visit for adjuvant therapy with gemcitabine and capecitabine', but the patient has already completed 6 cycles of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage description is imprecise. It should specify the stage at diagnosis rather than the current status. | Because of renal and splenic invasion, the left kidney and left adrenal and spleen were included in  |
| P2 | Treatment_Changes.recent_changes | Missing information about the completion of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Response_Assessment.response_assessment | The response assessment does not mention the completion of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Procedure_Plan.procedure_plan | The referral to hepatology is not clearly stated as a future plan. | We will refer him to hepatology for an evaluation. |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary of the visit, stage description, treatment changes, response assessment, and procedure plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 79 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma with metastatic disease to liver
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | current_meds | The field is empty, but the note mentions 'gemcitabine, irinotecan, oxaliplatin, leucovorin'. | phase III evidence supports either ***** (biweekly ***** 5-*****, leucovorin, irinotecan, and oxalip |
| P2 | Treatment_Goals | The field states 'palliative', but the note suggests a goal of achieving a deep and durable remission. | the mainstay of treatment at this juncture should consist of systemic therapy with the goal of achie |
| P2 | Lab_Results | The field includes 'Hemoglobin 14.0, Hematocrit 41.0, Platelet Count 166, Int'l Normaliz Ratio 1.0', which are not mentioned in the note. | Most recent labs notable for the following: Lab Results Component Value Date WBC Count 5.8 05/02/202 |

*Extraction summary*: Most fields are clean, but there are minor issues with current medications, treatment goals, and lab results.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P2 | The term 'adenocarcinoma' is used without further explanation, which might be confusing for an 8th-grade reading level. | You have been diagnosed with pancreatic adenocarcinoma (cancer that started in g |
| P2 | While 'CA 19-9' is not flagged for explanation, the term 'tumor marker' might still be too technical for an 8th-grade reading level. | Your CA 19-9 (a tumor marker) level is elevated at 852. |
| P2 | The list of drug names might be overwhelming and confusing for an 8th-grade reading level. | You will start a combination of chemotherapy drugs called a chemotherapy combina |
| P2 | The term 'MRI study' might be too technical for an 8th-grade reading level. | An MRI study will be conducted before starting treatment. |
| P2 | Terms like 'germline testing', 'hereditary predisposition', and 'molecular testing' might be too technical for an 8th-grade reading level. | Germline testing will be done to assess for any hereditary predisposition to can |

*Letter summary*: The letter contains minor readability issues that could be improved for an 8th-grade reading level.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication 'abraxane'. | Started ***** abraxane C1D1 08/03/18 |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 84 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (acyclovir). | Medication Sig acyclovir (ZOVIRAX) 400 mg tablet |
| P2 | Treatment_Changes | Missing supportive medication (PRBCs). | Due to persistent (rx-related) anemia on screening labs, he received 2u PRBCs at our infusion center |
| P2 | Lab_Plan | Should include regular monitoring of lab results. | Review of his CT scans show essentially stable to slightly enlarging sites of his measurable lesions |

*Extraction summary*: Most fields are clean, but there are minor issues regarding missing current cancer-related medications and supportive treatments, and lack of regular lab monitoring.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 87 — ⚠️ ISSUES

**Type**: Pancreatic neuroendocrine tumor, well-differentiated
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing 'octreotide', which is a cancer-related medication. | octreotide (SANDOSTATIN *****) 30 mg every 30 (thirty) days. |
| P2 | Treatment_Changes | Supportive medications listed incorrectly include 'nystatin (MYCOSTATIN) ointment', which is not cancer-related. | nystatin (MYCOSTATIN) ointment APPLY ON THE SKIN TWICE A DAY UNTIL ***** ***** RED. |
| P2 | Treatment_Goals | Goals of treatment should be 'palliative' but the note suggests 'possible slow PD', indicating a more complex situation. | Possible slow PD |
| P2 | Response_Assessment | The response assessment mentions 'some minimal progression' but does not specify the exact nature of the progression. | These findings suggest a slow progression despite ongoing treatment with everolimus. |
| P2 | Medication_Plan | Mentions 'metformin' which is not a cancer-related medication. | Continue Everolimus 10 mg daily. Continue octreotide. If progression, could consider temozolomide, [ |
| P2 | Procedure_Plan | Includes 'continue monitoring triglycerides quarterly' which is not a procedure plan. | Liver directed therapy might be an option, follow up MMA and B12, continue monitoring triglycerides  |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, incorrect classification of supportive medications, and slight imprecision in treatment goals and response assessment.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 90 — ⚠️ ISSUES

**Type**: Primary pancreatic neuroendocrine tumor; BRAF-mutant metastatic melanoma
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medications (dabrafenib and trametinib). | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Changes | Missing recent changes related to dabrafenib and trametinib. | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Goals | Goals of treatment should include both palliative and symptom management. | Patient has multiple hyperattenuating liver lesions, two of which are new from 05/17/2015, suspiciou |
| P2 | Response_Assessment | Missing response assessment for dabrafenib and trametinib. | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Medication_Plan | Missing medication plan for dabrafenib and trametinib. | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Imaging_Plan | Missing imaging plan for ongoing monitoring of melanoma and pNET. | Patient has multiple hyperattenuating liver lesions, two of which are new from  05/17/2015, suspicio |

*Extraction summary*: Most fields are clean, but there are minor omissions related to dabrafenib and trametinib, and a lack of imaging plan for ongoing monitoring.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Your dose of octreotide was reduced for four days, then increased for four days, |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 91 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas, moderately differentiated
**Stage**: Resected with 8 of 23 lymph nodes positive

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | The summary mentions 'potential recurrence' but does not specify the context of the current coronavirus crisis. | As long as he is asymptomatic, we will watch this as hope that it represents delayed post op changes |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage description is somewhat imprecise. It should include the resection status and lymph node involvement more clearly. | Resected with 8 of 23 lymph nodes positive |
| P2 | Treatment_Changes.recent_changes | There is no mention of recent changes in treatment, but the note suggests ongoing monitoring without immediate changes. | We'll see him again in 3 months for follow-up. |
| P2 | Response_Assessment.response_assessment | The response assessment does not fully capture the uncertainty regarding possible local recurrence due to the current situation. | He may well have local recurrence but with the current coronavirus crisis, it will be difficult to w |

*Extraction summary*: Most fields are accurate and complete, but there are minor issues with the summary and response assessment that could be more precise.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 92 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma with perineural and lymphova
**Stage**: Originally borderline resectable, now metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis | The extracted 'Type_of_Cancer' does not fully match the note. The note mentions 'moderately differentiated adenocarcinoma' but does not specify 'perineural and lymphovascular invasion'. | final pathology was notable for residual moderately differentiated adenocarcinoma with (+) marked tr |
| P2 | Lab_Results | The extracted 'lab_summary' includes redacted values for AST/ALT, which should be omitted. | WBC 14.3, Hct 41.2, plts 123, Creat 0.78, AST/ALT [REDACTED]/[REDACTED], tot bili 0.4, alk phos 115, |
| P2 | Current_Medications | The field is empty, but the note mentions ongoing chemotherapy with gemcitabine and [REDACTED]-paclitaxel. | she resumed chemotherapy with the combination of gemcitabine plus *****-paclitaxel |
| P2 | Treatment_Changes | The field is empty, but the note mentions a chemotherapy holiday and potential future treatments. | we will want to continue re-addressing the incorporation of a chemotherapy holiday at some point. |
| P2 | Treatment_Goals | The extracted 'goals_of_treatment' is 'palliative', but the note suggests a mix of palliative and surveillance goals. | assuming continued good disease control, we will want to continue re-addressing the incorporation of |
| P2 | Response_Assessment | The extracted 'response_assessment' is incomplete. It does not mention the stable disease status of the liver and lung lesions. | Postoperative scans have revealed no evidence of active disease in the liver and a slightly growing  |
| P2 | Medication_Plan | The extracted 'medication_plan' mentions trametinib, which is not part of the current plan but a future consideration. | Future considerations include incorporating a chemotherapy holiday at some point and exploring clini |
| P2 | Therapy_plan | The extracted 'therapy_plan' mentions trametinib, which is not part of the current plan but a future consideration. | Future considerations include incorporating a chemotherapy holiday at some point and exploring clini |
| P2 | Imaging_Plan | The extracted 'imaging_plan' is incomplete. It does not mention the specific timing of the next imaging, which is 2-3 months. | repeat imaging in another 2-3 months' time, unless her CA-119-9 markedly rises in the interim. |
| P2 | Lab_Plan | The extracted 'lab_plan' is incomplete. It does not mention the specific timing of the next lab tests, which is 2-3 months. | unless CA 19-9 markedly rises in the interim. |
| P2 | follow_up_next_visit | The extracted 'Next clinic visit' is incomplete. It does not mention the specific timing of the next visit, which is 2-3 months. | in-person: 2-3 months for repeat imaging |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and precision in several fields.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 98 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic ()

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and Abraxane) | We initially saw her about 2 months ago. We recommended therapy with gemcitabine and Abraxane. |
| P2 | Treatment_Changes | Supportive medications listed are incomplete | She was having a lot of difficulty with nausea and vomiting, early satiety and low caloric intake. W |
| P2 | Lab_Plan | Incorrect classification, should be under Therapy_plan | Once we can get her albumin up to 2 or better, we can resume her chemotherapy. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and incomplete supportive medications. Additionally, the lab plan is incorrectly classified.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

